Aurealis News
Aurealis Therapeutics Appoints Hanna P. Lesch, PhD, as Chief Technology Officer
Aurealis Therapeutics, a synthetic biology company developing multi-targeting, scalable, low cost of goods cell and gene therapies for high unmet medical needs, is proud to announce the appointment of Hanna...
Aurealis Therapeutics Announces Positive Blinded Evaluator Efficacy Results of “DIAMEND” Phase-2 Randomized Controlled Trial: AUP-16 Tripling the Complete Wound Closure Rate in Patients with Chronic Diabetic Foot Ulcers
Aurealis Therapeutics, a clinical-stage company developing scalable and low COGS multi-target cell and gene therapies for chronic wounds and cancer, today announced positive blinded evaluator efficacy results and completion of the...
Aurealis Therapeutics to Attend Swiss Biotech Day 2025
Aurealis Therapeutics, a synthetic biology company developing multi-targeting, scalable, low cost of goods cell and gene therapies for high unmet medical needs, announced today that Chief Operating Officer Laurent Décory will...
Aurealis Therapeutics Concludes Largest EWMA Participation to Date with Exciting Investigator Data of DIAMEND Phase 2 DFU Clinical Trial Presented by Prof. Alberto Piaggesi
Update — May 2026 The final blinded evaluator results have since been confirmed. See the DIAMEND Phase 2 results. Watch highlights video here. Aurealis Therapeutics, a synthetic biology company developing...
Aurealis Therapeutics Raises CHF 8 Million to Complete Phase 2 Clinical Studies in Chronic Wounds and Accelerate Oncology Program
Aurealis Therapeutics, a synthetic biology company developing multi-targeting, scalable, low cost of goods cell and gene therapies for high unmet medical needs, has raised CHF 8 million from existing investors...
Aurealis Therapeutics Announces Peer-Reviewed Paper Published from Phase 1 Study of AUP-16 for Non-Healing Diabetic Foot Ulcers
Update — May 2026 The AUP-16 Phase 1 DFU clinical study was followed by the DIAMEND Phase 2 clinical trial, which has since been completed. See the DIAMEND Phase 2 results....